MECURE

MeCure Industries Plc is a fast-growing Nigerian healthcare name posting 20% revenue growth and 41% EBIT growth in H1-2026, with a independently confirmed ROE of 37.84% that signals genuine franchise quality. However, at ₦56.20 the stock trades at 10.21x P/B versus a computed base fair value of ₦49.14, implying ~13% downside to fair value and a price already embedding a premium multiple regime that the company's short own-history cannot fully justify. The committee score (net score -2, 'cautious') confirms the risk-reward is unfavourable at current levels despite the underlying operational momentum.

Verdict published 2026-08-10 · fundamentals through Q2-2026 · reviewed as the data changes